Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor

Autor: Reedijk, M., Boucher, C. A.B., Bommel, T. V., Ho, D. D., Tzeng, T. B., Sereni, D., Veyssier, P., Jurriaans, S., Granneman, R., Hsu, A., Leonard, J. M., Danner, S. A.

Publikováno v: Antimicrobial agents and chemotherapy, 39(7), 1559-1564. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 39(7), 1559-1564. American Society for Microbiology
Reedijk, M, Boucher, C A B, Bommel, T V, Ho, D D, Tzeng, T B, Sereni, D, Veyssier, P, Jurriaans, S, Granneman, R, Hsu, A, Leonard, J M & Danner, S A 1995, ' Safety, pharmacokinetics, and antiviral activity of A77003, a C 2 symmetry-based human immunodeficiency virus protease inhibitor ', Antimicrobial Agents and Chemotherapy, vol. 39, no. 7, pp. 1559-1564 . https://doi.org/10.1128/AAC.39.7.1559

A77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, was administered to asymptomatic HIV-1-infected patients in a phase I trial. The drug was given by continuous intravenous infusion at dosages of 0.035, 0.07, 0.14, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04348edb973d8039d57239c9f0b4a7a8
https://pure.amc.nl/en/publications/safety-pharmacokinetics-and-antiviral-activity-of-a77003-a-c2-symmetrybased-human-immunodeficiency-virus-protease-inhibitor(a3373128-4da7-40f9-a1e2-fb8036585aba).html

Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats.

Autor: Tzeng, T B, Fung, H L

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; May 1992, Vol. 261 Issue: 2 p692-700, 9p

Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery

Autor: Borenstein, M., Shupak, R., Barnette, R., Cooney, G., Johnson, W., Tzeng, T.- B.

Publikováno v: European Journal of Clinical Pharmacology; January 1997, Vol. 51 Issue: 5 p359-366, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.